Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

A series of new revelations has come to light about the FDA's delay in granting full approval to Novavax's COVID-19 shot, thanks to recent reporting from the Wall Street Journal and STAT News.

Novavax (NVAX) is in focus after the company responded to the FDA's call for an additional clinical trial for its COVID-19 vaccine. Zscaler (ZS) was upgraded to Outperform from Neutral by BNP Paribas.

Novavax (NVAX) is in focus after the company responded to the FDA's call for an additional clinical trial for its COVID-19 vaccine. Zscaler (ZS) was upgraded to Outperform from Neutral by BNP Paribas.

Novavax (NVAX) is in focus after the company responded to the FDA's call for an additional clinical trial for its COVID-19 vaccine. Zscaler (ZS) was upgraded to Outperform from Neutral by BNP Paribas.

Novavax (NVAX) is in focus after the company responded to the FDA's call for an additional clinical trial for its COVID-19 vaccine. Zscaler (ZS) was upgraded to Outperform from Neutral by BNP Paribas.

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

According to an internal email, the agency may be in for more consolidation in areas including human resources, ...

The newly reconstituted CDC Advisory Committee on Immunization Practices will meet this week. Packed with antivaxxers, the ...

Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

This is the story of Birgenair flight 301.